0A05.LSE Medacta Group S.A.
- Market cap
- -
- P/E
- 45.5x
- P/B
- -
- ROE
- 34.4%
- Dividend yield
- 0.24%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0A05.LSE undervalued?
Graham numberThe Graham number of Medacta Group S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medacta Group S.A. fundamental analysis
No fundamental analysis for Medacta Group S.A. yet.
Medacta Group S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medacta Group S.A.
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
Full company profileMedacta Group S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medacta Group S.A. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 219M | 245M | 273M | 311M | 302M | 363M | 437M | 511M | 591M | 688M | 1.47B |
| Gross Profit | 165M | 183M | 204M | 224M | 214M | 261M | 305M | 348M | 399M | 441M | 956M |
| Operating Income | 49.9M | 50.4M | 61.7M | 40.1M | 49.4M | 58.8M | 61.5M | 74.4M | 74.4M | 116M | 216M |
| EBITDA | 67.5M | 71.7M | 84.7M | 73.1M | 90.1M | 107M | 121M | 134M | 157M | 191M | 385M |
| Net Income | 39.2M | 33.5M | 45.8M | 11.9M | 37.1M | 51.5M | 46.2M | 47.4M | 72.9M | 96.1M | 167M |
| EPS | 980 | 837 | 2.29 | 0.59 | 1.85 | 2.58 | 2.31 | 2.37 | 3.65 | 4.81 | 8.35 |
| Balance Sheet | |||||||||||
| Total Assets | 270M | 300M | 366M | 413M | 442M | 489M | 584M | 696M | 792M | 917M | 1.01B |
| Total Liabilities | 123M | 198M | 277M | 289M | 277M | 263M | 310M | 366M | 413M | 461M | 526M |
| Shareholders' Equity | 147M | 102M | 89.1M | 123M | 165M | 226M | 275M | 330M | 380M | 456M | 485M |
| Cash & Short-term Investments | 20.7M | 25.1M | 33.7M | 27.2M | 48.1M | 20.4M | 32.3M | 20.8M | 31.6M | 33.2M | 36.1M |
| Total Debt | 41.9M | 97.8M | 164M | 153M | 150M | 135M | 172M | 204M | 244M | 263M | 322M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 56.3M | 51.6M | 66.4M | 42.6M | 59.6M | 54.1M | 72.8M | 75.1M | 107M | 154M | 222M |
| Capital Expenditure | 21.2M | 30.3M | 45.2M | 41.5M | 27.3M | 46.5M | 62.5M | 69.7M | 89.3M | 124M | 278M |
| Free Cash Flow | 35.1M | 21.3M | 21.3M | 1.16M | 32.3M | 7.57M | 10.2M | 5.47M | 17.9M | 29.9M | -55.9M |
| Ratios | |||||||||||
| ROE | 26.7% | 32.9% | 51.4% | 9.6% | 22.5% | 22.8% | 16.8% | 14.4% | 19.2% | 21.1% | 34.4% |
| ROA | 14.5% | 11.2% | 12.5% | 2.9% | 8.4% | 10.5% | 7.9% | 6.8% | 9.2% | 10.5% | 16.5% |
| Net Profit Margin | 17.9% | 13.7% | 16.8% | 3.8% | 12.3% | 14.2% | 10.6% | 9.3% | 12.3% | 14.0% | 11.4% |
| Debt to Equity | 0.29x | 0.96x | 1.85x | 1.24x | 0.91x | 0.60x | 0.63x | 0.62x | 0.64x | 0.58x | 0.66x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medacta Group S.A. dividends
- Dividend yield
- 0.24%
- Forward dividend
- -
- Payout ratio
- 15.4%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 14.8M | 0.74 | 15.4% |
| 2024 | EUR 11.2M | 0.56 | 15.4% |
| 2023 | EUR 11.1M | 0.55 | 23.3% |
| 2022 | CHF 10.3M | 0.52 | 22.3% |
| 2021 | CHF 10.4M | 0.52 | 20.2% |
| 2020 | CHF 10.4M | 0.52 | 28.1% |
| 2019 | CHF 10.4M | 0.52 | 87.8% |
| 2018 | CHF 65.2M | 3.26 | 142.6% |
| 2017 | CHF 62.8M | 1,570 | 187.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Medacta Group S.A.
- Insiders 69.66%
- Institutions 13.07%
- Public & others 17.27%
- Free float 6.03M
Medacta Group S.A. company profile
- Company name
- Medacta Group S.A.
- Ticker
- 0A05.LSE
- ISIN
- CH0468525222
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 2,273
- Fiscal year end
- December
- Address
- Strada Regina, 34, Castel San Pietro, Switzerland, 6874
- Phone
- 41 91 696 60 60
- Website
- medacta.com
About Medacta Group S.A.
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
Medacta Group S.A. management
10- Dr. Alberto SiccardiFounder & Non Executive Chairman · born 1944
- Dr. Francesco SiccardiChief Executive Officer · born 1977
- Mr. Corrado FarsettaChief Financial Officer · born 1968
- Mr. Asif HussainChief People Officer · born 1971
- Mr. Alessandro SiccardiChief Supply Chain Officer · born 1986
- Filippo CappelliHead of IT
- Mr. Giovanni Niccolo GalliChief Commercial Officer · born 1976
- Mr. Massimiliano BernardoniChief Innovation Officer · born 1973
- Donato CortesiSecretary of the Board
- Antonio Di BrinoGroup Vice President of Finance & Tax